Roche Launches AXELIOS 1, A Next-Generation Sequencing Platform Combining Accuracy, Speed, Scalability And Cost Efficiency For Research Laboratories
هوفمان-لا روش
هوفمان-لا روش ADR
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications.
- Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours.
- The AXELIOS 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future.